At a glance
- Originator GlaxoSmithKline
- Class Anti-ischaemics; Antiparkinsonians; Heart failure therapies; Neuroprotectants
- Mechanism of Action Dopamine D1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer; Gastritis; Parkinson's disease
Most Recent Events
- 16 Nov 1999 No-Development-Reported for Cancer in USA (unspecified route)
- 28 Aug 1996 Preclinical development for Cancer in USA (unspecified route)
- 13 Mar 1995 Discontinued-Unspecified phase in Gastritis in United Kingdom (unspecified route)